Objectives In the US, chronic bronchitis (CB) is common and is associated with substantial morbidity and mortality. Data on CB in the Hispanic/Latino population—a large, diverse US minority—are scarce. We aimed to test whether the prevalence of CB varies across Hispanic/Latino heritages and to identify CB risk factors, including occupational exposures, in this population.
Methods We analysed data from the Hispanic Community Health Study/Study of Latinos, a US population-based probability sample of participants aged 18–74 years (n=16 415) including those with Mexican, Puerto Rican, Dominican, Cuban, Central American and South American heritages. Participants who had a completed respiratory questionnaire and valid spirometric data were included in the analysis (n=13 259). CB, place of birth, heritage, occupational exposures and other risk factors were based on standardised questionnaires. The prevalence of CB was estimated using survey logistic regression-conditional marginal analysis.
Results The estimated (mean (95% CI)) overall adjusted prevalence of CB was 12.1% (9.3 to 15.6), with a large variation across heritages. Dominican heritage had a fivefold higher prevalence than South American heritage. US-born participants had a higher adjusted prevalence than their non-US-born counterparts (16.8% (12.5 to 22.1) vs 11.0% (8.5 to 14.10); p=0.022). Compared with non-exposed participants, those exposed to cleaning or disinfecting solutions had a higher adjusted prevalence of CB (12.6% (9.1 to 17.1) vs 11.8% (9.2 to 15.1); p=0.024).
Conclusions The prevalence of CB was higher among Dominicans than other Hispanic/Latino heritages. CB was more prevalent among US-born participants and those exposed to cleaning and disinfecting solutions.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors AD and WW had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: all authors. Acquisition, analysis or interpretation of data: all authors. Drafting of the manuscript: VK and AD. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: WW. Obtained funding: AD. Supervision: AD.
Funding AD receives funding support from the National Heart, Lung, and Blood Institute of the NIH (award number R01-HL133137) and the Brigham and Women’s Hospital Minority Faculty Career Development Award.
Disclaimer This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors used the public data sets of HCHS/SOL, which may differ from those used for HCHS/SOL in their publications.
Competing interests VK has received personal fees from Medscape, Gala Therapeutics, AstraZeneca, Boehringer Ingelheim and the American Board of Internal Medicine over the last 3 years, outside of the submitted work. DM is an employee and shareholder of GlaxoSmithKline. AD reported receipt of grant funding from the National Institutes of Health (NIH) and the Brigham and Women's Hospital Minority Faculty Career Development Award.
Patient consent for publication Not required.
Ethics approval Informed consent was obtained from all study participants and HCHS/SOL was approved by each site’s IRB. The current study was approved by the Partners Human Research Committee (2017P001688/PHS).
Provenance and peer review Not commissioned; internally peer reviewed.
Data availability statement Data may be obtained from a third party and are not publicly available. Data are available upon reasonable request.